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Abstract
Animal models which allow the temporal regulation of gene activities are valuable for dissecting gene function in
tumorigenesis. Here we have constructed a conditional inducible estrogen receptor-K-ras
G12D (ER-K-ras
G12D) knock-in mice
allele that allows us to temporally switch on or off the activity of K-ras oncogenic mutant through tamoxifen administration.
In vitro studies using mice embryonic fibroblast (MEF) showed that a dose of tamoxifen at 0.05 mM works optimally for
activation of ER-K-ras
G12D independent of the gender status. Furthermore, tamoxifen-inducible activation of K-ras
G12D
promotes cell proliferation, anchor-independent growth, transformation as well as invasion, potentially via activation of
downstream MAPK pathway and cell cycle progression. Continuous activation of K-ras
G12D in vivo by tamoxifen treatment is
sufficient to drive the neoplastic transformation of normal lung epithelial cells in mice. Tamoxifen withdrawal after the
tumor formation results in apoptosis and tumor regression in mouse lungs. Taken together, these data have convincingly
demonstrated that K-ras mutant is essential for neoplastic transformation and this animal model may provide an ideal
platform for further detailed characterization of the role of K-ras oncogenic mutant during different stages of lung
tumorigenesis.
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Introduction
Animal models which allows temporal regulation of gene
activity have been proved very valuable for gaining insights into
the gene function involved in different tumor formation stages.
Previous studies have demonstrated that knock-in of ER region
into certain genes including P53 and Myc to generate fusion
proteins allow for precise and temporal regulation of gene activity
via ectopic provision of 4-hydroxytamoxifen [1,2]. The Trp53ER
KI/KI mouse model is the first example of genetic models that
allows specific, rapid and reversible perturbation of the biological
function of a single endogenous gene in vivo. Studies based on this
mouse model have dissected the precise role of P53 engaged in
different stages of tumorigenesis as well as tumor regression
[2,3,4,5,6,7,8]. Similarly, studies using the MycER mouse
allelesignificantly contribute to our understanding about the role
of Myc in cell proliferation, differentiation as well as the
relationship between stem cells and cancer [1,6,7,9,10,11,12].
Oncogenic mutations including K-RAS
G12D is frequently
observed in approximately 20% of all types of human cancers
including carcinomas of the lung, colon, and pancreas
[13,14,15,16,17,18]. K-RAS is a small GTPase which works as a
binary molecular switch between a GDP-bound inactive form and
a GTP-bound active form. When mutated in codon 12, 13, or 61,
the K-RAS mutants remain active and constitutively transduce
signals through MAPK pathway and PI3K pathway [19,20,21,22].
Previous studies have demonstrated that proteins such Ras or Raf
fused to ER could be activated by tamoxifen treatment
[23,24,25,26,27]. However, there is no animal model has been
established based on this knowledge yet.
We have here engineered a knock-in allele encoding a 4-
hydroxy tamoxifen (4-OHT) inducible estrogen receptor-K-ras
G12D
(ER-K-ras
G12D) with placing the Loxp-Stop-Loxp fragment in front
of the exon 1 of K-ras coding region. Using the mouse embryonic
fibroblast (MEF), we have shown that ER-K-ras
G12D expression is
induced by Adeno-Cre treatment and the activity of ER-K-
ras
G12D mutant is regulated by an optimal dose of tamoxifen
administration. We further demonstrated that the ER-K-ras
G12D
mutant is essential for neoplastic transformation as well as tumor
maintenance.
Materials and Methods
Mouse cohorts and Treatment
The K-ras
G12D and p53 L/L mice were originally generously
provided by T. Jacks (Cambridge, MA) and R. Depinho (Boston,
MA), respectively. The LSL-ER-K-ras
G12D mice allele was con-
structed by placing the estrogen receptor cDNA in front of the K-
ras
G12D coding region as shown in Figure 1. The targeting vector
carried a negative selection marker for diptheria toxin (DT), a
positive selection marker for neomycin acetyltransferase (Neo) and
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37308loxP sites (black triangles). The restriction sites were BamH I (B);
Kpn I (K); Not I (N); Xba I (Xb); Sph I (S). We electroporated
embryonic stem cells and selected transformed cells by 39 arm and
59 arm PCR screening to identify 3 recombinants. Blastocyst
injections were carried out with these different targeted clones and
germline transmission was achieved. The LSL-ER-K-ras
G12D mice
were then crossed to p53 L/L mice to obtain LSL-ER-K-ras
G12D,
p53L/L mice. All mice were housed in a specific pathogen-free
environment at Shanghai Institute of Biochemistry and Cell
Biology and treated in strict accordance with protocols approved
by the Institutional Animal Care and Use Committee of the
Shanghai Institute of Biochemistry and Cell Biology, Chinese
Academy of Sciences. These mice were treated with Adeno-Cre
through nasal inhalation as described before [28]. After three
weeks of nasal inhalation, we treated these mice with 4-hydroxy-
tamoxifen with different doses daily via intraperitoneal injection.
Mice were then sacrificed for pathological inspection. Some mice
were stopped for tamoxifen treatment for one or two weeks and
then sacrificed for pathological inspection. Genotyping primers for
p53L/L, LSL-K-ras
G12D and LSL-ER-K-ras
G12D was listed as
following: For p53L/L, forward primer: 59-CACAAAAACAGGT-
TAAACCCAG-39; reverse primer: 59-AGCACATAGGAGGCA-
GAGAC-39. For LSL-K-ras
G12D and LSL-ER-K-ras
G12D, same
primers were used for genotyping. Forward primer: 59-CTAGC-
CACCATGGCTTGAGT-39; reverse primer:59-TCCGAATT-
CAGTGACTACAGATG-39.
Cell culture and cell proliferation assay
We generated MEFs from 13.5 post-coitum embryos and grew
them in DMEM medium plus 10% fetal bovine serum (Biochrom,
AG), penicillin and streptomycin. MEFs (,4610
5) at 6-well plate
were virally infected with Adeno-Cre (4610
6 CFU) overnight and
then changed with fresh medium. The MEFs were then cultured
for at least two more passages to get enough cells for various
functional assays. Cell number were counted after each passage
with or without tamoxifen treatment. Cells were also taken for PI
staining and flow cytometry analysis for cell cycle.
Biochemical assay
Total RNA was prepared and retro-transcribed into first-strand
cDNA using RevertAid
TM First Strand cDNA Synthesis Kit
(Fermentas Cat: K1622). The cDNAs were then used for either
regular PCR or real-time PCR on a 7500 Fast Real-Time PCR
System (Applied Biosystems) using SYBR-Green Master PCR mix
(Toyobo). b-actin served as internal control. Purification of gDNA
in cells and mice tissues were previously described [29]. Primers
used for RT-PCR were listed as following: For K-ras
G12D, forward
primer: 59-TAAACTTGTGGTGGTTGGAG-39; reverse primer:
59-AACTCCTGAGCCTGTTTCGT-39. For ER- K-ras
G12D, for-
ward primer: 59-TCTACTTCATCGCATTCCTTG-39; reverse
primer: 59-GGCACATCTTCAGAGTCCTTT-39. For b-actin,
forward primer: 59-CGTTGACATCCGTAAAGACC-39; reverse
Figure 1. Establishment of a conditional regulatable K-ras
G12D knock-in allele. A) Construction of Loxp-Stop-Loxp-ER-K-ras
G12D mice allele.
The Stop codon were flanked with two LoxP sites; the Neo cassette is flanked with two FRT sites; Positive selection cassette contains the gene for a
viral Neo cassette and negative selection cassette contains the gene for a viral thymidine kinase (TK). The original mice were then crossed with b-
actin-Flpe to delete the Neo cassette. Thymidine kinase (TK); BamH I (B); Kpn I (K); Not I (N); Xba I (Xb); Sph I (S); ER, estrogen receptor cDNA; *, GGT to
GAT mutation at codon 12; B) The genomic DNA recombination was confirmed by the 59arm and 39arm PCR. C) Detection of mRNA level of either K-
ras or ER-K-ras
G12D in indicated MEFs. The PCR primers used for ER-K-ras
G12D amplification are located at ER region and K-ras exon 2 respectively. b-
actin serves as control. (D) Sequencing results confirmed the expression of the ER-K-ras gene fusion in MEFs.
doi:10.1371/journal.pone.0037308.g001
A Temporally Regulatable ER-K-ras
G12D Mouse Allele
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real-time PCR were listed as following: For K-ras
G12D, forward
primer: 59-TGTGGATGAGTATGACCCTA-39; reverse prim-
er:59-TACACAAAGAAAGCCCTCCCCA-39. For ER-K-ras
G12D,
forward primer: 59-TTTCCCTGCCACAGTCCC-39; reverse
primer: 59-TCCATCAATTACTACTTGTTTCCTG-39. For b-
actin, forward primer: 59-CAGCCTTCCTTCTTGGGTAT-39;
reverse primer: 59-GGTCTTTACGGATGTCAACG-39. Primers
for detection of mouse gender using gDNA were listed as
following: For Sry, forward primer: 59- TGGTCCCGTGGTGA-
GAGGC -39; reverse primer: 59- TATGTGATGG-
CATGTGGGTTCC -39. For IL3,5 9- GGGACTCCAAGCTT-
CAATCA -39; reverse primer: 59-
TGGAGGAGGAAGAAAAGCAA -39.
Total protein lysate were prepared by homogenization in
protein loading buffer. Equal amounts of protein from each
sample were separated by electrophoresis on an SDS-PAGE gel
and transferred onto PVDF membranes. Western blot analysis was
performed using following antibodies towards: Ras (Millipore, Cat:
05-1072), ER (Santa Cruz Cat: sc-543), Phospho-Raf (Cell
Signaling, Cat: 9427), total Raf (Santa Cruz Cat: sc-5284),
Phospho-Erk (Cell Signaling, Cat: 9180), total Erk (Santa Cruz
Cat: sc-153), Phospho-Akt, Phospho-GSK (Cell Signaling, Cat:
9916), total Akt (Cell Signaling, Cat: 9272), total GSK (Bioworld
Technology, Cat: BS1412), Cyclin d1, Cdk4, Cdk6, p15 (Cell
Signaling, Cat: 9932), Cyclin B1 (Bioworld Technology, Cat:
BS1392), Cdc2 (Bioworld Technology, Cat: BS1820) and b-actin
(Santa Cruz, SC-1616).
Cellular functional assay
MEFs with indicated genotype with or without tamoxifen
(Sigma, Cat: 011M1682V) treatment were cultured in DMEM
with 10% fetal bovine serum until 100% confluence. MEFs were
changed with fresh medium every three days for 3 weeks before
staining with 0.005% crystal violet. Foci formation were observed
and the number of foci were counted.
As for anchorage-independent cell growth, MEFs were plated in
0.4% top agarose on top of a 1% agarose base supplemented with
complete medium. MEFs were changed with fresh medium with
or without tamoxifen every 3 days for about 4 weeks before
staining with 0.005% crystal violet. The number of colonies
(.0.5 mm) were counted under the microscope.
As for invasion assay, MEFs were cultured in matrigel (BD, Cat:
356234) in the presence or absence of tamoxifen treatment for 10
days. Photos with typical morphologic change were shown.
Figure 2. Treatment of tamoxifen at an optimal dose induced the activation of ER-K- ras
G12D and downstream signaling. A) The
P532/2, ER-K-ras
G12D MEFs (PEK-C) derived from male embryo was counted for cell number after indicated dosage of tamoxifen treatment after 5
passages. B) Relative expression level of K-ras in indicated MEFs with or without tamoxifen treatment. PEK: P53L/L, Loxp-Stop-Loxp ER-K-ras
G12D; PEK-C:
P532/2, ER-K-ras
G12D; PK: P53L/L, Loxp-Stop-Loxp-K- ras
G12D; PKC: P532/2, K- ras
G12D. (C) Detection of the ER-K-ras
G12D expression in PEK-C cells with
or without 0.05 mM tamoxifen treatment. D) Detection of K-ras and ER-K-ras protein level in MEFs infected with or without adeno-Cre in the presence
or absence of 0.05 mM tamoxifen treatment in indicated MEFs. b-actin serves as internal control. E) The activation of Ras effector PI3K pathway
signaling was confirmed by western blot.
doi:10.1371/journal.pone.0037308.g002
A Temporally Regulatable ER-K-ras
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Histopathological analysis were performed as described before
[30]. Briefly, mice were sacrificed and lung tissues were inflated
and fixed in 10% formalin, embedded in paraffin and sectioned for
hematoxylin and eosin (HE) staining. For immunostaining,
sections of 5 mm-thickness were cut from paraffin-embedded lung
tissues, deparaffinized in xylene and rehydrated in ethanol.
Deparaffinized sections were pretreated with 0.3% H2O2 (in
absolute methanol) for 15 min at room temperature to block
endogenous peroxidase activity. The slides were then heated in a
microwave for three periods of 5 min high power, 2 min defrost
and 20 min medium low power of microwave treatments. After re-
cooling at room temperature for about 30 min, slides were rinsed
twice in H2O for 3 min and then were treated for 2 h with normal
non- immune goat serum albumin to block nonspecific staining.
Sections were incubated overnight with Ki67 antibody (1:100,
Santa Cruz, SC-23900) and Cleaved Caspase-3 antibody (1:300,
Cell Signaling, Cat: 9661). The secondary biotinylated antibody
was incubated for 15 min at 37uC. The slides were then stained
using a diaminobenzidine tetrahydrochloride (DAB) detection kit
(SP-9001), counterstained with haematoxylin and mounted with
permount.
Results
Establishment of the knock-in mice with an endogenous
conditional regulatable LSL-ER-K-ras
G12D allele
We have made the conditional regulatable LSL-ER-K-ras
G12D
knock-in allele using the homologous recombination with the
replacement of endogenous K-ras with a fragment containing of a
1.0 kb estrogen receptor cDNA fused to the K-ras
G12D (Fig. 1A).
The mice were then crossed with b-actin-Flpe to delete the Neo
cassette and the resultant mouse allele was named as LSL-ER-K-
ras
G12D. The homologous recombination were confirmed by the
59arm and 39arm PCR as described before (Fig. 1B) [31]. We
obtained the LSL-ER-K-ras
G12D mouse embryonic fibroblasts
(MEFs) and infected them with Adeno-Cre. As expected we have
detected the expression of ER-K-ras
G12D at mRNA level (Fig. 1C),
which was further confirmed by direct sequencing (Fig. 1D).
Activation of ER-K-rasG12D and downstream signaling by
tamoxifen treatment
We next determined if the ER-K-ras
G12D MEFs are responsive to
tamoxifen treatment. Tamoxifen is an anti-breast cancer agent
and potentially toxic. We therefore titrated its dosage for the ER-
K-ras
G12D MEF treatment. Interestingly, we found that the
Figure 3. Induced activation of ER-K-ras
G12D by tamoxifen treatment promoted cell proliferation. A) The induced activation of ER-K-
ras
G12D by tamoxifen treatment promoted cell entry into G2/M phase detected by FACS assay in PEK-C MEFs. B) Western blot analysis of cell cycle-
related proteins in PEK-C MEFs with or without tamoxifen treatment. The PEK MEFs were used as control. b-actin serves as internal control for western
blot. C) Cell number counting of indicated MEFs cultured for 6 passages with or without tamoxifen treatment.
doi:10.1371/journal.pone.0037308.g003
A Temporally Regulatable ER-K-ras
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dose from 0.0125 mM to 0.05 mM (Figure S2A–B). However,
decreased cell proliferation was observed when an even higher
dose of tamoxifen (from 0.1 mM to 0.2 mM) was given to MEFs
(Figure S2A–B). Similar finding was observed in the ER-K-ras
G12D
MEFs with p53 deficient background (Fig. 2A and Figure S2C).
Furthermore, both ER-K-ras
G12D and p532/2, ER-K-ras
G12D
MEFs (PEK-C) from either male or female has shown consistent
response to tamoxifen treatment (Fig. 2A, Figure S1, Figure S2),
suggesting a gender-independent pattern. Hereafter, we chose a
dose of tamoxifen at 0.05 mM for further in vitro studies. P53 loss is
commonly observed in human cancer [32]. Moreover, p53
deficiency results in the immortalization of MEFs and also
significantly contributes to colony formation of K-ras
G12D MEFs
in soft agar. For these reasons, we have therefore used the p532/
2, ER-K-ras
G12D MEFs (refer to PEK-C) for our further studies.
We compared the mRNA level of total K-ras in p53L/L, LSL-ER-
K-ras
G12D (PEK), p532/2, ER-K-ras
G12D (PEK-C) and p532/2,
K-ras
G12D (PK-C) MEFs (Fig. 2B) as well as LSL-K-ras
G12D, LSL-ER-
K-ras
G12D, ER-K-ras
G12D MEFs with or without Adeno-Cre
treatment (Figure S3A–C). No significant change of total K-ras
mRNA and protein levels was observed among all MEFs with or
without either Adeno-Cre or tamoxifen treatment (Fig. 2C–D).
Using K-ras antibody, we have detected the ER-K-ras band with
correct molecular weight (Fig. 2D). This was further confirmed by
western blot using ER antibody (Figure S3D). Consistently, we
have observed the phosphorylation of several Ras downstream
effectors including Raf, Erk, Akt and Gsk after tamoxifen
treatment (Fig. 2E).
Inducible activation of ER-K-ras
G12D promotes cell
proliferation
Abnormal cell proliferation is considered as an early event
during tumorigenesis [33]. Tamoxifen administration significantly
increased the cell division in MEFs indicated by an increase of cells
at G2/M phase (Fig. 3A). Increase of cell cycle related proteins
including Cyclin d1, Cdk4, Cdk6, p15, Cyclin b1, and Cdc2 were
also observed (Fig. 3B). Conversely, p27 protein level decreased
after tamoxifen treatment (Fig. 3B). We further checked the cell
proliferation rate of PEK, PK-C, and PEK-C with or without
tamoxifen treatment using cell number counting for 6 passages.
We found that the tamoxifen treatment significantly increased cell
proliferation in PEK-C MEFs. Actually, the growth rate of PEK-C
MEFs treated with 0.05 mM tamoxifen is comparable to PK-C
MEFs. Taken together, these data have demonstrated that ER-K-
ras activation by tamoxifen treatment promoted cell proliferation
in vitro.
Activation of ER-K-ras
G12D is essential for cell
transformation and cell invasiveness
We then determined if the inducible ER-K-ras activation
promotes cell transformation, anchorage-independent cell growth
Figure 4. Induction of ER-K-ras
G12D activation by tamoxifen treatment is important for cell transformation and cell invasiveness in
vitro. A) The foci formation assay were performed in PEK-C MEFs with or without tamoxifen administration. Bar graph indicated the number of foci
observed in one well in 6-well plate. B) The PEK-C MEFs were assayed for anchorage-independent cell growth ability in soft agar in the absence or
presence of tamoxifen administration. Bar graph indicated the colonies observed in soft agar per well in 6-well plate. C) The PEK-C MEFs were
cultured in matrigel in the absence or presence of tamoxifen for indicated days and the cell invasiveness were assay as described in materials and
methods.
doi:10.1371/journal.pone.0037308.g004
A Temporally Regulatable ER-K-ras
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MEFs didn’t form any foci. Tamoxifen treatment of PEK-C MEFs
obviously promoted the foci formation, comparable to PK-C
MEFs (Fig. 4A). The anchor-independent growth of PEK-C MEFs
was also enhanced by activation of ER-K-ras
G12D after tamoxifen
treatment (Fig. 4B). These data have demonstrated that the ER-K-
ras
G12D activation is essential for cell transformation. Consistently,
we found that tamoxifen administration significantly increased cell
invasion in matrigel, suggesting that ER-K-ras
G12D activation by
tamoxifen treatment may promote cell invasion (Fig. 4C).
Continuous activation of ER-K-ras
G12D induced lung
hyperplasia
RAS mutant play a pivotal role in neoplastic transformation and
tumorigenesis [13,19,34,35,36]. To test the in vivo function of ER-
K-ras in lung tumorigenesis, we first tried tamoxifen treatment at
different doses in mice. All the p53L/L, LSL-ER-K-ras
G12D mice
were given Adeno-Cre at 6,8 week-old. After three weeks of
Adeno-Cre treatment, these mice were then given tamoxifen daily
via intraperitoneal (IP) injection. Our pilot experiment has used a
series of different tamoxifen doses at 0, 100, 250, 500, 1000 mg per
mouse. All the mice without tamoxifen treatment showed normal
lung histology (Fig. 5B and Figure S4). Mice with low doses of
tamoxifen treatment at 100 or 250 mg displayed normal lung
pathology, similar to those with a higher dose of tamoxifen at
1000 mg (Figure S4). Interestingly, mice receiving tamoxifen at
500 mg were found to have lung hyperplasia as early as after 5-
week treatment (Figure S4). Lung adenomas, positive for Ki-67
staining, arose at 8 weeks post tamoxifen treatment (Fig. 5A).
These data suggested that an optimal dose of tamoxifen is
sufficient to drive lung epithelial cell proliferation, hyperplasia and
early tumor formation.
Continuous activation of ER-K-ras
G12D is important for
tumor maintenance
To further test the potential role of K-ras mutant in tumor
maintenance, we have performed both in vitro and in vivo studies. As
we have shown above, tamoxifen treatment significantly promoted
PEK-C MEFs proliferation after several passages (Fig. 3C).
However, after tamoxifen withdrawal, these MEFs obviously
reduced the proliferation rate in comparison with PK-C MEFs
(Fig. 6A). Similarly, tamoxifen withdrawal resulted in a dramatic
decrease of the colony formation ability and cell invasiveness of
these MEFs (Fig. 6B–C).
Our data have shown that continuous tamoxifen treatment at
an optimal dose for 12 weeks consistently drove lung hyperplasia
formation in p53L/L, LSL-ER-K-ras
G12D after Adeno-Cre treat-
ment (Fig. 5). We then stopped tamoxifen treatment afterwards for
either 1 week or 2 week. Pathological inspection have shown that
the lung hyperplasia significantly decreased in mouse lungs even
after one week of tamoxifen withdrawal (Fig. 6D). The tumor
regression is accompanied by apoptosis indicated by increased
cleaved caspase-3 immunostaining (Figure 6D). The mouse lungs
were largely normal after two weeks of tamoxifen withdrawal
(Fig. 6D), suggesting that continuous activation of K-ras mutant is
important for tumor maintenance.
Discussion
Temporal controlling K-ras activity in vitro and in vivo is of great
importance for dissection of its function in tumorigenesis. We have
here constructed a conditional inducible oestrogen receptor-K-
ras
G12D (ER-K-ras
G12D) knock-in mice allele that allows us to
temporally switch on or off the K-ras oncogenic mutant through
the tamoxifen administration. This allele is able to be regulated by
tamoxifen treatment at an optimal dosage in vitro and in vivo. Our
data have demonstrated that the deregulation of K-ras activity
Figure 5. Continuous activation of ER-K-ras
G12D by 500 mg tamoxifen treatment induced lung hyperplasia and adenoma formation
in P53 L/L, LSL-ER-K-ras mice. A) Continuous activation of ER-K-ras
G12D by 500 mg tamoxifen I.P. daily injection for 12 weeks is sufficient to drive
lung adenoma formation in P53 L/L, LSL-ER-K-ras mice after adeno-Cre treatment. The adenoma were positive for Ki67 immunostaining. B) The
incidence of lung hyperplasia and/or adenoma formation in P53L/L, LSL-ER-K-ras
G12D mice was shown after adeno-Cre treatment in the absence or
presence of tamoxifen treatment.
doi:10.1371/journal.pone.0037308.g005
A Temporally Regulatable ER-K-ras
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tumor maintenance.
Several animal models have been generated to study the role of
K-ras mutant in tumorigenesis [28,33,37,38]. Animal model with
oncogenic alleles of K-ras
LA was initially constructed via homolo-
gous recombination [37]. The K-ras
LA mice have developed a
variety of tumor types including lung neoplastic transformation
[37]. However, an early mortality was caused by an overwhelming
number of predominantly early-stage lung lesions which limits the
capacity for tumor progression [37]. A transgenic mouse allele
with doxycycline-inducible K-ras4B
G12D expression was estab-
lished under the control of rat Clara cell secretory protein CCSP
promoter [38]. Although this mouse allele has been proved to be
very helpful in the regulation of K-ras expression with time, it’s a
transgenic line with potentially multiple copies and uncertain
genomic insertion sites which may influence the function of K-ras
mutant. A significantly improved animal model was generated by
placing a Loxp-stop-Loxp cassette fragment in front of K-ras
G12D
coding region, in which the K-ras mutant doesn’t express until the
removal of stop codon by either Adeno-Cre treatment or tissue-
specific CRE transgene expression [28,33]. This model has been
widely used for cancer studies, especially for the study on tumor
initiation and progression process [4,7,29,39,40]. With this model,
once the K-ras mutant is activated, it can’t be turned off, which
may limit it’s usage in studying tumor maintenance. Our animal
model with ER knock-in into K-ras gene allele allows us to
temporally control the K-ras activity via tamoxifen administration,
which makes it possible to dissect the role of K-ras mutant at
different stages of tumorigenesis.
Tamoxifen is an anti-estrogen commonly used in the treatment
of breast cancer. Previous studies have showed that a dosage range
between 10 nM to 1 mM is able to inhibit cell growth [41,42].
Therefore, the tamoxifen stimulation of ER-fusion protein
activation may somehow be dependent on the dosage. Consis-
tently, a 4OHT concentration-dependent induction of fusion
protein activity were also observed previously
[1,24,25,26,27,43,44]. In our study, we have observed that a dose
of tamoxifen at 0.05 mM works effectively for stimulating the
activation of ER-K-ras
G12D and cell proliferation. However, we
are not certain about the optimal dosage of tamoxifen for in vivo
treatment. As we know, it usually takes about more than 20 weeks
for us to observe tumor nodules on lung surface in K-ras
G12D mouse
model [45] and our unpublished data). In contrast, simultaneous
p53 deficiency with K-ras activation significantly facilitates lung
tumor progression. Most K-ras
G12D mice with p53 deficiency
develop large tumors on lung surface at 10 weeks post Adeno-Cre
treatment [46]. To shorten the potential tamoxifen treatment
duration and make our in vivo study more practical, we have
therefore tested the tamoxifen dosage in P53L/L, ER-K-ras
G12D
mice after Adeno-Cre treatment. Interestingly, we have found that
Figure 6. Sustained activation of ER-K-ras
G12D induced by tamoxifen treatment is important for cell proliferation, anchorage-
independent cell growth, cell invasiveness and tumor maintenance. A) Cell number counting of indicated MEFs after withdrawal of
tamoxifen after 6 passages in the presence of tamoxifen. The PEK-C MEFs always without tamoxifen treatment and the PEK-C MEFs always kept in
tamoxifen were used as control. B) Tamoxifen were withdrawn from the PEK-C MEFs at day 5, 10 and 28 after continuous tamoxifen treatment in soft
agar. C) Tamoxifen withdrawal from the PEK-C MEFs after indicated days of tamoxifen treatment in cell invasiveness assay in matrigel. D) Tamoxifen
withdrawal for indicated time in the P53L/L, LSL-ER-K-ras
G12D mice previously treated for 12 weeks of tamoxifen. The typical lung pathology and
cleaved caspase-3 immunostaining were shown.
doi:10.1371/journal.pone.0037308.g006
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hyperplasia in P53L/L, ER-K-ras
G12D mice. However, the tumor
latency is much longer than that of the P53L/L, K-ras
G12D mouse
model. It takes about 12 weeks of tamoxifen treatment for the
P53L/L, ER-K-ras
G12D mice to develop lung tumors. One
possibility for this could be the low level of ER-K-ras
G12D
activation by tamoxifen treatment at 500 mg. Future study is
definitely necessary to optimize the tamoxifen dosage to achieve
the full-activation of ER-K-ras
G12D.
In sum, we have here constructed a mice allele with regulatable
K-ras and demonstrated that the activation of K-ras is important
for tumor formation as well as tumor maintenance. This animal
model may provide a useful platform for further detailed
characterization of the role of K-ras during different stages of
tumorigenesis.
Supporting Information
Figure S1 Genotyping of MEFs. A) Genotyping of Loxp-Stop-
Loxp-K-ras
G12D before and after Adeno-Cre treatment in different
MEFs. B) Genotyping of p53 MEFs before and after Adeno-Cre
treatment in different MEFs.
(TIF)
Figure S2 0.05 mM tamoxifen treatment induced
Ras
G12D activation both in male and female ER-K-
ras
G12D MEFs (A and B) and in PEK-C female MEFs (C).
(TIF)
Figure S3 The expression of K-ras and ER-K-ras on
mRNA and protein level in different MEFs. A) The
expression of K-ras has no obvious change on mRNA level in
Loxp-Stop-Loxp-K-ras
G12D MEFs and Loxp-Stop-Loxp-ER-K-
ras
G12D with or without Adeno-Cre treatment. B-C) The
expression of ER-K-ras
G12D has no obvious change on mRNA
level in ER-K-ras MEFs in the absence (B) or in the presence (C) of
tamoxifen treatment. D) Detection of ER and ER-K-Ras protein
level in MEFs infected with or without Adeno-Cre in the presence
or absence of 0.05 mM tamoxifen treatment in indicated MEFs. b-
actin serves as internal control.
(TIF)
Figure S4 500 mg per mouse per day tamoxifen treat-
ment could induce ER-K-ras
G12D activation and lead
lung hyperplasia (A and B).
(TIF)
Acknowledgments
The authors thank Li Li, Feng Liu, Wei Bian, Xiaoyan Wang for technical
support.
Author Contributions
Conceived and designed the experiments: HJ XL KW NB. Performed the
experiments: ZW YF HJ. Analyzed the data: ZW HJ. Contributed
reagents/materials/analysis tools: ZW XL KW NB HJ. Wrote the paper:
ZW KW HJ.
References
1. Arnold I, Watt FM (2001) c-Myc activation in transgenic mouse epidermis
results in mobilization of stem cells and differentiation of their progeny. Curr
Biol 11: 558–568.
2. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L,
et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet
37: 718–726.
3. Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegue E, et al. (2011)
Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
Genes Dev 25: 1746–1757.
4. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, et al. Selective
activation of p53-mediated tumour suppression in high-grade tumours. Nature
468: 567–571.
5. Ringshausen I, O’Shea CC, Finch AJ, Swigart LB, Evan GI (2006) Mdm2 is
critically and continuously required to suppress lethal p53 activity in vivo.
Cancer Cell 10: 501–514.
6. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007)
Restoration of p53 function leads to tumour regression in vivo. Nature 445:
661–665.
7. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, et al. (2010)
Stage-specific sensitivity to p53 restoration during lung cancer progression.
Nature 468: 572–575.
8. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic
efficacy of p53 restoration in tumors. Cell 127: 1323–1334.
9. Soucek L, Nasi S, Evan GI (2004) Omomyc expression in skin prevents Myc-
induced papillomatosis. Cell Death Differ 11: 1038–1045.
10. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, et al. (2007)
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced
model of lymphoma. J Clin Invest 117: 326–336.
11. Yu D, Carroll M, Thomas-Tikhonenko A (2007) p53 status dictates responses of
B lymphomas to monotherapy with proteasome inhibitors. Blood 109:
4936–4943.
12. Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI (2009) Acute
overexpression of Myc in intestinal epithelium recapitulates some but not all
the changes elicited by Wnt/beta-catenin pathway activation. Mol Cell Biol 29:
5306–5315.
13. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49:
4682–4689.
14. Croce CM (2008) Oncogenes and cancer. N Engl J Med 358: 502–511.
15. Rodenhuis S (1992) ras and human tumors. Semin Cancer Biol 3: 241–247.
16. Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, et al. (2009) Clinical
implications of KRAS mutations in lung cancer patients treated with tyrosine
kinase inhibitors: an important role for mutations in minor clones. Neoplasia 11:
1084–1092.
17. Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, et al. (2007) Nras and Kras
mutation in Japanese lung cancer patients: Genotyping analysis using Light-
Cycler. Oncol Rep 18: 623–628.
18. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, et al. (1996) K-ras
oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer
Res 56: 2224–2228.
19. Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, et al. (2008) RAS
signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/
or RASSF1A. Neoplasia 10: 680–686, 682 p following 686.
20. Liu L, Zhu S, Gong Z, Low BC (2008) K-ras/PI3K-Akt signaling is essential for
zebrafish hematopoiesis and angiogenesis. PLoS One 3: e2850.
21. Wells V, Downward J, Mallucci L (2007) Functional inhibition of PI3K by the
betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation.
Oncogene 26: 7709–7714.
22. Menges CW, McCance DJ (2008) Constitutive activation of the Raf-MAPK
pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular
arrest through the EphA2 receptor. Oncogene 27: 2934–2940.
23. Lim KH, Counter CM (2005) Reduction in the requirement of oncogenic Ras
signaling to activation of PI3K/AKT pathway during tumor maintenance.
Cancer Cell 8: 381–392.
24. Ambesi A, Klein RM, Pumiglia KM, McKeown-Longo PJ (2005) Anastellin, a
fragment of the first type III repeat of fibronectin, inhibits extracellular signal-
regulated kinase and causes G(1) arrest in human microvessel endothelial cells.
Cancer Res 65: 148–156.
25. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, et al. (2005)
Development of a conditional in vivo model to evaluate the efficacy of small
molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
Cancer Res 65: 9962–9970.
26. Tarutani M, Cai T, Dajee M, Khavari PA (2003) Inducible activation of Ras
and Raf in adult epidermis. Cancer Res 63: 319–323.
27. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ (2004) Blocking the Raf/
MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-
induced apoptosis. Cancer Res 64: 6461–6468.
28. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis
of lung tumor initiation and progression using conditional expression of
oncogenic K-ras. Genes Dev 15: 3243–3248.
29. Ji HB, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1
modulates lung cancer differentiation and metastasis. Nature 448: 807–U807.
30. Gao Y, Xiao Q, Ma H, Li L, Liu J, et al. (2010) LKB1 inhibits lung cancer
progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl
Acad Sci U S A 107: 18892–18897.
31. Fujimoto K, Arakawa S, Shibaya Y, Miida H, Ando Y, et al. (2006)
Characterization of phenotypes in Gstm1-null mice by cytosolic and in vivo
metabolic studies using 1,2-dichloro-4-nitrobenzene. Drug Metab Dispos 34:
1495–1501.
A Temporally Regulatable ER-K-ras
G12D Mouse Allele
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e3730832. Blagosklonny MV (2002) P53: an ubiquitous target of anticancer drugs.
Int J Cancer 98: 161–166.
33. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, et al. (2004)
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread
neoplastic and developmental defects. Cancer Cell 5: 375–387.
34. Mahgoub N, Parker RI, Hosler MR, Close P, Winick NJ, et al. (1998) RAS
mutations in pediatric leukemias with MLL gene rearrangements. Genes
Chromosomes Cancer 21: 270–275.
35. Quinlan MP, Quatela SE, Philips MR, Settleman J (2008) Activated Kras, but
not Hras or Nras, may initiate tumors of endodermal origin via stem cell
expansion. Mol Cell Biol.
36. Kohno T, Kunitoh H, Suzuki K, Yamamoto S, Kuchiba A, et al. (2008)
Association of KRAS Polymorphisms with Risk for Lung Adenocarcinoma
Accompanied by Atypical Adenomatous Hyperplasias. Carcinogenesis.
37. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001)
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.
Nature 410: 1111–1116.
38. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, et al. (2001)
Induction and apoptotic regression of lung adenocarcinomas by regulation of a
K-Ras transgene in the presence and absence of tumor suppressor genes. Genes
Dev 15: 3249–3262.
39. Mukhopadhyay A, Krishnaswami SR, Yu BD (2011) Activated Kras alters
epidermal homeostasis of mouse skin, resulting in redundant skin and defective
hair cycling. J Invest Dermatol 131: 311–319.
40. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, et al.
(2009) TGF-beta receptor inactivation and mutant Kras induce intestinal
neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology
136: 1680–1688 e1687.
41. Osborne CK, Hobbs K, Clark GM (1985) Effect of estrogens and antiestrogens
on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:
584–590.
42. Briand P, Lykkesfeldt AE (1986) Long-term cultivation of a human breast cancer
cell line, MCF-7, in a chemically defined medium. Effect of estradiol. Anticancer
Res 6: 85–90.
43. Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, et al. (2009) Lrig1
expression defines a distinct multipotent stem cell population in mammalian
epidermis. Cell Stem Cell 4: 427–439.
44. Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in
beta cells exposes multiple oncogenic properties of Myc and triggers
carcinogenic progression. Cell 109: 321–334.
45. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, et al. (2009) HIF2alpha
cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119:
2160–2170.
46. Hammoud Z, Tan B, Badve S, Bigsby RM (2008) Estrogen promotes tumor
progression in a genetically defined mouse model of lung adenocarcinoma.
Endocr Relat Cancer 15: 475–483.
A Temporally Regulatable ER-K-ras
G12D Mouse Allele
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37308